Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 ± IL-15

Genetic Vaccines and Therapy

Volumn 2, Issue , 2004, Pages

  McKee, Hayley J ^a   T'sao, Patricia Y ^a   Vera, Maria ^b   Fortes, Puri ^b   Strayer, David S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cytotoxic memory; HIV 1 gp120; IL 15; SV40

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GLYCOPROTEIN GP 120; INTERLEUKIN 15; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BINDING ASSAY; CELL ASSAY; CELL LINE; CELL MATURATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG SPECIFICITY; EFFECTOR CELL; GENE DELETION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; MEMORY CELL; MONOTHERAPY; MOUSE; MOUSE STRAIN; MULTIPLE DRUG DOSE; NONHUMAN; SIMIAN VIRUS 40; SPLEEN CELL; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

EID: 16344392139     PISSN: 14790556     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-0556-2-10     Document Type: Article

References (38)

1. Swann SA, Williams M, Story CM, Bobbitt KR, Fleis R, Collins KL: HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 2001, 282:267-277.
2. Graziosi C, Soudeyns H, Rizzardi GP, Bart P-A, Chapuis A, Pantaleo G: Immunopathogenesis of HIV infection. AIDS Res Hum Retrovir 1998, 14(Suppl 2):S135-S142.
3. McMichael A: T cell responses and viral escape. Cell 1998, 93:673-676.
4. Haynes BF: Wb#HIV vaccines: where we are and where we are going. Lancet 1996, 348:933-937.
5. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D: The selective downregulation of class I major histocompatability complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671.
6. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G, and the HIVNET: Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001, 183:1343-1352.
7. Ramirez J-C, Gherardi MM, Rodriguez D, Esteban M: Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000, 74:7651-7655.
8. Molinier-Frenkel V, Gahery-Segard H, Mehtali M, Le Boulaire C, Ribault S, Boulanger P, Tursz T, Guillet JG, Farace F: Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000, 74:7678-7682.
9. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette A, Altman JD, Moss B, McMichael AJ, Watkins DI: Induction of AIDS virus-specific CTL activity in fresh unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000, 164:4968-4978.
10. Salmon-Ceron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S: Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AIDS Res Hum Retrovir 1999, 15:633-645.
11. Kondo R, Feitelson MA, Strayer DS: Use of SV40 to immunize against hepatitis B surface antigen: Implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther 1998, 5:575-582.
12. McKee HJ, Strayer DS: Immune responses against SIV envelope glycoprotein using recombinant SV40 as a vaccine delivery vehicle. Vaccine 2002, 20:3613-3625.
13. Sauter BV, Parashar B, Chowdhury NR, Kadakol A, Ilan Y, Singh H, Milano J, Strayer DS, Chowdhury JR: A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology 2000, 119: 348-1357.
14. Norkin LC: Simian virus 40 infection via class I molecules and caveolae. Immunol Rev 1999, 168:13-22.
15. Pelkmans L, Kartenbeck J, Helenius A: Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nature Cell Biol 2001, 3:473-483.
16. Pelkmans L, Puntener D, Helenius A: Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 2002, 296:535-539.
17. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ: Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002, 76:243-250.
18. Barouch DH, Letvin NL: Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. Dev Biol (Basel) 2000, 104:85-92.
19. Bradney CP, Sempowski GD, Liao H-X, Haynes BF, Staats HF: Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002, 76:517-524.
20. Geginat J, Sallusto F, Lanzavecchia A: Cytokine-driven proliferation and differentiation of human naïve, central memory and effector memory CD4+ T cells. J Exp Med 2001, 194: 711-1719.
21. Sharif-Askari E, Fawaz LM, Tran P, Ahmad A, Menezes J: Interleukin 15-mediated induction of cytokine effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst 2001, 93:1724-1732.
22. Yajima T, Nishimura H, Ishimitsu R, Watase T, Busch DH, Pamer EG, Kuwano H, Yoshikai Y: Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol 2002, 168:1198-1203.
23. McMichael AJ: HIV. The immune response. Curr Opin Immunol 1996, 8:537-539.
24. Burton DR: A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci USA 1997, 94:10018-10023.
25. Johnson RP, Siliciano RF, McElrath MJ: Cellular immune responses to HIV-1. AIDS 1998, 12(Suppl A):S113-S120.
26. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ: HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 1999, 5:518-525.
27. Autran B, Hadida F, Haas G: Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol 1996, 8: 46-553.
28. Schmitz JE, Kuroda MJ, Santra S, Sasseviolle VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
29. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
30. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995, 69:5838-5842.
31. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJR, Walker BD, and the HIV Controller Study Collaboration: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001, 98:1781-1786.
32. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgog N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker B: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
33. Newman MJ: Heterologous prime-boost vaccination strategies for HIV-1: Augmenting cellular immune responses. Curr Opin Investig Drugs 2002, 3:374-378.
34. Strayer DS: Effective gene transfer using viral vectors based on SV40. in Methods in Molecular Biology, Gene Targeting Vector Protocols Volume 133. Edited by: Kmiec EB. Humana Press, New York; 1999:61-74.
35. de la Luna S, Martin J, Portela A, Ortin J: Influenza virus naked RNA can be expressed upon transfection into cells coexpressing the three subunits of the polymerase and the nucleoprotein from simian virus 40 recombinant viruses. J Gen Virol 1993, 74:535-539.
36. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF: Cytokine interactions in human immunodeficiency virus infected individuals: Roles of interleukin (IL)-2, IL-12 and IL-15. J Exp Med 1995, 182: 067-1077.
37. Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH, Cosman D: Il-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukocyte Biol 1995, 57: 63-766.
38. Armitage RJ, Mcduff BM, Eisenman J, Paxton R, Grabstein KH: Il-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 1995, 154: 83-490.